Psilocybin news for Las Vegas and Nevada
Rule changes, research and safety news that affect people in Las Vegas and Nevada, newest first. Every story links to the official record or the study it's based on.
From our sister shop, My Mushroom Dispensary. Adults 21+ only.
We cover Nevada's law and Legislature, the federal agencies that decide psilocybin's status (the FDA and the DEA), the licensed programs in Oregon, Colorado and New Mexico that Nevadans can travel to, and published research. Each post says what happened, what the primary record shows and what happens next. Corrections are made in the open, as our editorial standards describe.
- Is psilocybin on Nevada's 2026 ballot?
Nevada's two statewide questions are about abortion rights and voter ID. Idaho votes on who may legalize drugs.
- New Mexico holds a hearing on its medical psilocybin patient rule
New Mexico heard its medical psilocybin patient rule on October 2, 2026. We found no sign it was final by November 2.
- National survey estimates 8.1 million US adults used psilocybin in a year
A JAMA Network Open letter puts past-year psilocybin use at 3.1% of US adults. The health effects are self-reported.
- DEA proposes Schedule I for five tryptamines, none of them psilocybin
4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT. Psilocybin and psilocin are already Schedule I.
- Oregon drops its plan to double psilocybin license fees
Oregon withdrew its proposed 2027 psilocybin license fee increases on September 22, 2026. The budget gap remains.
- FDA's Sept. 14 hearing: how approved psychedelics might reach patients
The FDA asked about training, safety, access and data for future approved psychedelics. Comments closed Oct. 5.
- Oregon says 2,114 psilocybin clients came from other states
Oregon says 2,114 psilocybin clients had come from other states as of March 31, 2026. Nevada isn't counted separately.
- What a JAMA study of 346 Oregon psilocybin clients found
346 Oregon psilocybin clients: 4 serious reactions, self-reported gains, no control group and two corrections.
- Compass says its psilocybin application should be complete in late 2026
Compass expects to finish its FDA application in Q4 and launch in 2027 if approved. Nevada's 60-day rule explained.
- VA starts a 240-veteran psilocybin trial, with no site in Nevada
PIVOT tests psilocybin for treatment-resistant depression at five VA sites. None is in Nevada.
- FDA finalizes its guidance on how psychedelic drug trials should run
Two monitors per session, caution on placebos and longer follow-up: what the July 14 FDA guidance asks of studies.
- Colorado's new natural medicine law: an ibogaine pilot and on-site sales
Colorado's HB26-1325 creates an ibogaine pilot and a license to sell to participants right before a session.
Follow along with the RSS feed.